CA3242904A1 - VEGF-BINDING AND TIE2 FUSION PROTEIN AND ITS USES - Google Patents

VEGF-BINDING AND TIE2 FUSION PROTEIN AND ITS USES

Info

Publication number
CA3242904A1
CA3242904A1 CA3242904A CA3242904A CA3242904A1 CA 3242904 A1 CA3242904 A1 CA 3242904A1 CA 3242904 A CA3242904 A CA 3242904A CA 3242904 A CA3242904 A CA 3242904A CA 3242904 A1 CA3242904 A1 CA 3242904A1
Authority
CA
Canada
Prior art keywords
fusion protein
identity
seq
cancer
vegf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3242904A
Other languages
English (en)
French (fr)
Inventor
Minkyung Choo
Kwangsoo Kim
Sangyeul Han
Philip Durost
Original Assignee
Ingenia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ingenia Therapeutics Inc filed Critical Ingenia Therapeutics Inc
Publication of CA3242904A1 publication Critical patent/CA3242904A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3242904A 2022-01-13 2023-01-12 VEGF-BINDING AND TIE2 FUSION PROTEIN AND ITS USES Pending CA3242904A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263299177P 2022-01-13 2022-01-13
US63/299,177 2022-01-13
US202263310359P 2022-02-15 2022-02-15
US63/310,359 2022-02-15
US202263335805P 2022-04-28 2022-04-28
US63/335,805 2022-04-28
PCT/US2023/060582 WO2023137395A1 (en) 2022-01-13 2023-01-12 Vegf and tie2-binding fusion protein and uses thereof

Publications (1)

Publication Number Publication Date
CA3242904A1 true CA3242904A1 (en) 2025-03-14

Family

ID=87279731

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3242904A Pending CA3242904A1 (en) 2022-01-13 2023-01-12 VEGF-BINDING AND TIE2 FUSION PROTEIN AND ITS USES

Country Status (16)

Country Link
US (1) US20230287109A1 (https=)
EP (1) EP4463482A4 (https=)
JP (1) JP2025503704A (https=)
KR (1) KR20250005053A (https=)
AU (1) AU2023206363A1 (https=)
CA (1) CA3242904A1 (https=)
CL (2) CL2024002106A1 (https=)
CO (1) CO2024010934A2 (https=)
CR (1) CR20240342A (https=)
DO (1) DOP2024000136A (https=)
GE (1) GEAP202416581A (https=)
IL (1) IL314219A (https=)
JO (1) JOP20240158A1 (https=)
MX (1) MX2024008737A (https=)
PE (1) PE20260003A1 (https=)
WO (1) WO2023137395A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025178471A1 (ko) * 2024-02-20 2025-08-28 주식회사 맵틱스 Tie2 및 vegf에 특이적으로 결합하는 이중 특이적 항체 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX359833B (es) * 2011-08-19 2018-10-12 Regeneron Pharma Anticuerpos anti-tie2 y usos de los mismos.
JP2020501508A (ja) * 2016-09-15 2020-01-23 クアドルセプト バイオ リミテッド 多量体、四量体および八量体
EP3805265A4 (en) * 2018-06-07 2022-07-06 Institute for Basic Science ANTIBODIES BINDING TO TIE2 AND USES THEREOF
US10597453B2 (en) * 2018-06-29 2020-03-24 Gensun Biopharma, Inc. Antitumor immune checkpoint regulator antagonists
WO2020068653A1 (en) * 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
JP7638989B2 (ja) * 2019-11-21 2025-03-04 ユニティ バイオテクノロジー インコーポレイテッド Ｔｉｅ－２に対する抗体および使用方法
AU2021242249A1 (en) * 2020-03-24 2022-08-18 Genentech, Inc. Tie2-binding agents and methods of use

Also Published As

Publication number Publication date
WO2023137395A1 (en) 2023-07-20
CL2025002473A1 (es) 2025-11-14
CL2024002106A1 (es) 2025-03-28
JOP20240158A1 (ar) 2024-07-14
PE20260003A1 (es) 2026-01-06
MX2024008737A (es) 2024-09-11
EP4463482A4 (en) 2026-05-06
CO2024010934A2 (es) 2024-10-31
CR20240342A (es) 2024-09-18
US20230287109A1 (en) 2023-09-14
EP4463482A1 (en) 2024-11-20
IL314219A (en) 2024-09-01
AU2023206363A1 (en) 2024-08-15
KR20250005053A (ko) 2025-01-09
JP2025503704A (ja) 2025-02-04
GEAP202416581A (en) 2024-12-10
DOP2024000136A (es) 2024-10-15

Similar Documents

Publication Publication Date Title
US12157771B2 (en) Proteins binding NKG2D, CD16 and CLEC12A
JP6898303B2 (ja) Ｓｉｒｐ−アルファドメインまたはそのバリアントを有する構築物
US9856462B2 (en) Method of treating eye disease using glycosylated VEGF decoy receptor fusion protein
US20250051413A1 (en) Chimeric molecules comprising il-12 agonist polypeptide
KR20100128291A (ko) Ｅｇｆｒ에 결합하는 조작된 단백질을 기초로 하는 표적화된 치료제
US12466887B2 (en) Antibody binding to PD-1
AU2010230855A1 (en) Anti-VEGF-D antibodies
KR20190031246A (ko) VE-PTP (HPTP-β)를 표적으로 하는 인간화된 단클론성 항체
CN115925977B (zh) 双特异性融合多肽及其应用
KR20190124350A (ko) RGMa 결합 단백질 및 그 사용
US20230295258A1 (en) Fusion protein comprising il-12 and anti-fap antibody, and use thereof
US20250230248A1 (en) Anti-egfr antibodies, anti-cmet antibodies, anti-vegf antibodies, multispecific antibodies, and uses thereof
JP2025523049A (ja) 抗Ｎｅｃｔｉｎ－４抗体及びその使用
CN117529494A (zh) 包括il-12激动剂多肽的嵌合分子
US20230287109A1 (en) VEGF and TIE2-Binding Fusion Protein and Uses Thereof
US12473367B2 (en) Bispecific agonistic antibodies to activin a receptor like type 1 (ALK1)
EP4559932A1 (en) Multispecific antibody and use thereof
HK40118737A (zh) 结合vegf和tie2的融合蛋白及其用途
CN118922443A (zh) 结合VEGF和Tie2的融合蛋白及其用途
CN116829586A (zh) 用于治疗眼部疾病的抗-VEGF及抗-TrkB双特异性结合分子
KR20140025836A (ko) 항 ＨＥＲ2/Ｎｅｕ 단일클론항체와 ＩＬ-7가 연결된 융합 단일클론 항체 및 이를 포함하는 암 치료용 조성물
TWI916327B (zh) 結合pd-1的抗體
EP4737479A1 (en) 4-1bb-binding protein
WO2025070337A1 (ja) 抗ＭｅｒＴＫアゴニスト抗体、抗ＭｅｒＴＫ二重特異性抗体、及びその使用
WO2025140497A1 (zh) Pvrig结合蛋白、双特异性抗体及其应用

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240702

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240702

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240702

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR PRIORITY RECEIVED

Effective date: 20240702

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20240702

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W005 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: FIRST IPC ASSIGNED

Effective date: 20240702

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: IPC ASSIGNED

Effective date: 20240702

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W270 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: SEQUENCE LISTING - RECEIVED

Effective date: 20240702

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240703

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: IPC ASSIGNED

Effective date: 20240703

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W005 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: FIRST IPC ASSIGNED

Effective date: 20240703

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20240704

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20240722

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION)

Effective date: 20250314

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251217